Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of the Combination of Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Inoperable Well-Differentiated Neuroendocrine Tumors

NCT01203306 is registered in ClinicalTrials.gov with University of Turin, Italy as lead sponsor.

NCT NCT01203306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01203306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of the Combination of Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Inoperable Well-Differentiated Neuroendocrine Tumors
Lead sponsor
University of Turin, Italy
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2006
Completion date
December 31, 2010
Enrollment
42 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine carcinomas